الفهرس 
ABSTRACTOnly 14 pages are availabe for public view
 |  | from | 121 |  |  |
| | | from | 121 | | |
Abstract
Psoriasis is an auto-inflammatory disease characterized by a chronic skin inflammation with infiltrations containing T lymphocytes, neutrophils and macrophages. Increasing evidence from other Th17-mediated diseases such as multiple sclerosis and rheumatoid arthritis suggests that B cells might be equally important players. In psoriasis, B cells were indeed detected in lesional skin, and altered frequencies of circulating B lymphocytes in psoriasis have been described.
The chemokine CXC ligand 13 protein (CXCL13), also known as B cell- attracting chemokine-1 (BAC-1) or B lymphocyte chemoattractant (BLC), is a CXC subtype member of the chemokine superfamily. CXCL13 has been described as the most effective chemoattractant for B cells
Dysregulation of the CXCL13 affecting B-cell function and has a major role in autoimmune disorders, and potentially serves as a biomarker for disease progression and therapeutic response. Because of its impact on immune responses in autoimmunity, we hypothesized that CXCL13 is of pathogenic importance in pathogenesis of psoriasis disease.
This present study aimed to evaluate serum level of CXCL13 in psoriasis and correlation of it with disease severity.
The study was a case-control study that had been conducted from March 2021 to September 2021, in the Dermatology outpatient clinic at Beni-Suef University Hospital after the approval of REC on 30 psoriasis patients (22 males and 8 females), their age ranged from 18 to 50 years, the average age was 38.50 ±10.64, and 30 healthy controls with age and sex matched to the psoriasis cases. All participants underwent complete history taking. Measurement of CXCL13 serum level was conducted by CXCL13 Human ELISA kit according to the manufacturer’s instructions.
Our data analyses reveled that Serum CXCL13 level was significantly higher in psoriasis patients as compared with healthy controls. We reported a moderate positive significant linear correlation between serum level of CXCL13 with extent (%) and clinical severity of psoriasis as assessed by PASI score. We didn’t find any association between serum levels with patients’ age, gender, family history, disease onset, course and duration.
Our study suggests that CXCL13 is involved in the pathophysiology of psoriasis, and a possible association with disease severity. Better characterization of role of CXCL13 could constitute a therapeutic avenue to the treatment of psoriasis disease.